OBJECTIVE: To evaluate whether myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) rate in overweight women. METHODS: In an open-label, randomized trial, myo-inositol (2 g plus 200 μg folic acid twice a day) or placebo (200 μg folic acid twice a day) was administered from the first trimester to delivery in pregnant overweight non-obese women (pre-pregnancy body mass index ≥ 25 and < 30 kg/m(2)). The primary outcome was the incidence of GDM. RESULTS:From January 2012 to December 2014, 220 pregnant women were randomized at two Italian University hospitals, 110 to myo-inositol and 110 toplacebo. The incidence of GDM was significantly lower in the myo-inositol group compared to the placebo group (11.6% versus 27.4%, respectively, p = 0.004). Myo-inositol treatment was associated with a 67% risk reduction of developing GDM (OR 0.33; 95% CI 0.15-0.70). CONCLUSIONS:Myo-inositol supplementation, administered since early pregnancy, reduces GDM incidence in overweight non-obese women.
RCT Entities:
OBJECTIVE: To evaluate whether myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) rate in overweight women. METHODS: In an open-label, randomized trial, myo-inositol (2 g plus 200 μg folic acid twice a day) or placebo (200 μg folic acid twice a day) was administered from the first trimester to delivery in pregnant overweight non-obesewomen (pre-pregnancy body mass index ≥ 25 and < 30 kg/m(2)). The primary outcome was the incidence of GDM. RESULTS: From January 2012 to December 2014, 220 pregnant women were randomized at two Italian University hospitals, 110 to myo-inositol and 110 to placebo. The incidence of GDM was significantly lower in the myo-inositol group compared to the placebo group (11.6% versus 27.4%, respectively, p = 0.004). Myo-inositol treatment was associated with a 67% risk reduction of developing GDM (OR 0.33; 95% CI 0.15-0.70). CONCLUSIONS:Myo-inositol supplementation, administered since early pregnancy, reduces GDM incidence in overweight non-obesewomen.
Entities:
Keywords:
Body mass index; gestational diabetes; myo-inositol; obese; overweight
Authors: Jasmine F Plows; Clare M Reynolds; Mark H Vickers; Philip N Baker; Joanna L Stanley Journal: Curr Diab Rep Date: 2019-08-01 Impact factor: 4.810
Authors: Reshma A Pillai; Mohammed O Islam; Preben Selvam; Neha Sharma; Anne H Y Chu; Oliver C Watkins; Keith M Godfrey; Rohan M Lewis; Shiao Y Chan Journal: J Clin Endocrinol Metab Date: 2021-01-23 Impact factor: 5.958